Bekker, Rebecca A.
Obertopp, Nina
Redler, Gage
Penagaricano, José
Caudell, Jimmy J.
Yamoah, Kosj
Pilon-Thomas, Shari
Moros, Eduardo G.
Enderling, Heiko
Funding for this research was provided by:
National Institutes of Health (U01CA244100)
Article History
Received: 6 February 2024
Accepted: 26 August 2024
First Online: 13 September 2024
Declarations
:
: All tissues used in this study were collected as part of two IRB approved studies: Total Cancer Care (MCC#14690) and Using Radiotherapy to Perturb the Tumor-Immune Ecosystem for Immune-Modulated Tumor Control (MCC#19233), with patients providing written informed consent.
: Not applicable.
: Moffitt Cancer Center has licensed Intellectual Property (IP) related to the proliferation and expansion of tumor infiltrating lymphocytes (TILs) to Iovance Biotherapeutics. Moffitt has also licensed IP to Tuhura Biopharma. SPT is an inventor on such Intellectual Property. SPT is listed as a co-inventor on a patent application with Provectus Biopharmaceuticals. SPT participates in sponsored research agreements with Provectus Biopharmaceuticals, Iovance Biotherapeutics, Intellia Therapeutics, Dyve Biosciences, Turnstone Biologics, and Celgene that are not related to this research. SPT has received consulting fees from Seagen Inc., Morphogenesis, Inc., and KSQ Therapeutics. RAB, NO, GR, JP, KY, EGM and HE declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.